Vascular targets for cannabinoids: Animal and human studies

British Journal of Pharmacology

Volumn 171, Issue 6, 2014, Pages 1361-1378

  Stanley, Christopher ^a   O'Sullivan, Saoirse E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

artery; endocannabinoid; PPAR; prostanoid; TRPV1; vasoconstriction; vasorelaxation

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; G PROTEIN COUPLED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTANOID RECEPTOR; PROTEIN GPR55; SEROTONIN 1A RECEPTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

BLOOD VESSEL REACTIVITY; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; REVIEW; VASOCONSTRICTION; VASODILATATION;

ARTERY; CB1; CB2; ENDOCANNABINOID; PPAR; PROSTANOID; TRPV1; VASOCONSTRICTION; VASORELAXATION;

ANIMALS; BLOOD VESSELS; CANNABINOIDS; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 84895733033     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12560     Document Type: Review

References (139)

1. Abdulnour J, Yasari S, Rabasa-Lhoret R, Faraj M, Petrosino S, Piscitelli F, et al. (2014). Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study. Obesity (Silver Spring) 22: 211-216.
2. Alexander SP, Kendall DA, (2007). The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 152: 602-623. (Pubitemid 350034984)
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G-Protein Coupled Receptors. Br J Pharmacol 170: 1459-1581.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors. Br J Pharmacol 170: 1652-1675.
6. AlSuleimani YM, Hiley CR, (2013). Mechanisms of vasorelaxation induced by oleoylethanolamide in the rat small mesenteric artery. Eur J Pharmacol 702: 1-11. doi: 10.1016/j.ejphar.2013.01.006. Epub 2013 Jan 20.
7. Atwood BK, Wager-Miller J, Haskins C, Straiker A, Mackie K, (2012). Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol Pharmacol 81: 250-263.
8. Awumey EM, Hill SK, Diz DI, Bukoski RD, (2008). Cytochrome P-450 metabolites of 2-arachidonoyl glycerol play a role in Ca2+-induced relaxation of rat mesenteric arteries. Am J Physiol Heart Circ Physiol 294: H2363-H2370.
9. Baranowska-Kuczko M, MacLean MR, Kozlowska H, Malinowska B, (2012). Endothelium-dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery. Pharmacol Res 66: 251-259.
10. Baranowska-Kuczko M, Kozlowska H, Kloza M, Kozlowski M, Malinowska B, (2013). Role of endothelial mechanisms in anandamide-evoked vasorelaxant effects in human pulmonary arteries. Proceedings of the BPS 6th European Workshop on Cannabinoid Research 2013 P050.
11. Begg M, Mo FM, Offertaler L, Bátkai S, Pacher P, Razdan RK, et al. (2003). G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. J Biol Chem 278: 46188-46194. (Pubitemid 37432770)
12. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, et al. (2006). Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55: 3053-3060. (Pubitemid 44923642)
13. Bondarenko A, Waldeck-Weiermair M, Naghdi S, Poteser M, Malli R, Graier WF, (2010). GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells. Br J Pharmacol 161: 308-320.
14. Bukoski RD, Batkai S, Jarai Z, Wang Y, Offertaler L, Jackson WF, et al. (2002). CB(1) receptor antagonist SR141716A inhibits Ca(2+)-induced relaxation in CB(1) receptor-deficient mice. Hypertension 39: 251-257. (Pubitemid 34165224)
15. Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG, (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol 159: 129-141.
16. Chaytor AT, Martin PEM, Evans WH, Randall MD, Griffith TM, (1999). The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol 520: 539-550. (Pubitemid 29511916)
17. Chen C, Jin X, Meng X, Zheng C, Shen Y, Wang Y, (2011). Inhibition of TNFalpha-induced adhesion molecule expression by (Z)-(S)-9-octadecenamide, N-(2-hydroxyethyl,1-methyl). Eur J Pharmacol 660: 305-309.
18. Chen P, Hu S, Yao J, Moore SA, Spector AA, Fang X, (2005). Induction of cyclooxygenase-2 by anandamide in cerebral microvascular endothelium. Microvasc Res 69: 28-35. (Pubitemid 40416723)
19. Corriu C, Feletou M, Canet E, Vanhoutte PM, (1996). Endothelium-derived factors and hyperpolarization of the carotid artery of the guinea-pig. Br J Pharmacol 119: 959-964. (Pubitemid 26366492)
20. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP, et al. (2007). Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 31: 692-699. (Pubitemid 46482358)
21. Czikora A, Lizanecz E, Boczan J, Darago A, Papp Z, Edes I, et al. (2012). Vascular metabolism of anandamide to arachidonic acid affects myogenic constriction in response to intraluminal pressure elevation. Life Sci 90: 407-415.
22. Daly CJ, Ross RA, Whyte J, Henstridge CM, Irving AJ, McGrath JC, (2010). Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid-like' receptors in small arteries. Br J Pharmacol 159: 787-796.
23. Dannert MT, Alsasua A, Herradon E, Martín MI, Lõpez-Miranda V, (2007). Vasorelaxant effect of Win 55,212-2 in rat aorta: new mechanisms involved. Vasc Pharmacol 46: 16-23. (Pubitemid 44856374)
24. De Petrocellis L, Starowicz K, Moriello AS, Vivese M, Orlando P, Di Marzo V, (2007). Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. Exp Cell Res 313: 1911-1920. (Pubitemid 46661844)
25. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, et al. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Investigation 100: 1538-1546. (Pubitemid 27425781)
26. Domenicali M, Ros J, Fernández-Varo G, Cejudo-Martín P, Crespo M, Morales-Ruiz M, et al. (2005). Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut 54: 522-527. (Pubitemid 40395505)
27. Ellis EF, Moore SF, Willoughby KA, (1995). Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. Am J Physiol Heart Circ Physiol 269: H1859-H1864.
28. Engeli S, Bluher M, Jumpertz R, Wiesner T, Wirtz H, Bosse-Henck A, et al. (2012). Circulating anandamide and blood pressure in patients with obstructive sleep apnea. J Hypertens 30: 2345-2351.
29. Fleming I, Schermer B, Popp R, Busse R, (1999). Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. Br J Pharmacol 126: 949-960. (Pubitemid 29103711)
30. Gasperi V, Dainese E, Oddi S, Sabatucci A, Maccarrone M, (2013). GPR55 and its interaction with membrane lipids: comparison with other endocannabinoid-binding receptors. Curr Med Chem 20: 64-78.
31. Gauthier KM, Baewer DV, Hittner S, Hillard CJ, Nithipatikom K, Reddy DS, et al. (2005). Endothelium-derived 2-arachidonoyl glycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. Am J Physiol Heart Circ Physiol 288: H1344-H1351. (Pubitemid 40270043)
32. Gebremedhin D, Lange AR, Campbell WB, Hillard CJ, Harder DR, (1999). Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol Heart Circ Physiol 276: H2085-H2093. (Pubitemid 29323495)
33. Ghosh M, Wang H, Ai Y, Romeo E, Luyendyk JP, Peters JM, et al. (2007). COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J Exp Med 204: 2053-2061. (Pubitemid 47360868)
34. Godlewski G, Offertáler L, Osei-Hyiaman D, Mo FM, Harvey-White J, Liu J, et al. (2009). The endogenous brain constituent N-arachidonoyl L-serine is an activator of large conductance Ca2+-activated K+ channels. J Pharmacol Exp Ther 328: 351-361.
35. Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, et al. (2004). Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 132: 87-92. (Pubitemid 39531355)
36. Grainger J, Boachie-Ansah G, (2001). Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br J Pharmacol 134: 1003-1012. (Pubitemid 33052159)
37. Harris D, McCulloch AI, Kendall DA, Randall MD, (2002). Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed. J Physiol 539 (Pt 3): 893-902. (Pubitemid 35175438)
38. Hauer D, Schelling G, Gola H, Campolongo P, Morath J, Roozendaal B, et al. (2013). Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLoS One 8: e62741.
39. Henstridge CM, Balenga NAB, Ford LA, Ross RA, Waldhoer M, Irving AJ, (2009). The GPR55 ligand L-{alpha}-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 23: 183-193.
40. Herradõn E, Martín MI, Lõpez-Miranda V, (2007). Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br J Pharmacol 152: 699-708. (Pubitemid 350034972)
41. Ho WS, Hiley CR, (2003). Endothelium-independent relaxation to cannabinoids in rat-isolated mesenteric artery and role of Ca2+ influx. Br J Pharmacol 139: 585-597. (Pubitemid 36819628)
42. Ho WS, Barrett DA, Randall MD, (2008). 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 155: 837-846.
43. Hoi PM, Hiley CR, (2006). Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. Br J Pharmacol 147: 560-568. (Pubitemid 43355054)
44. Hopps JJ, Dunn WR, Randall MD, (2012). Enhanced vasorelaxant effects of the endocannabinoid-like mediator, oleamide, in hypertension. Eur J Pharmacol 684: 102-107.
45. Inoue I, Shino K, Noji S, Awata T, Katayama S, (1998). Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 246: 370-374. (Pubitemid 28412605)
46. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96: 14136-14141.
47. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, et al. (2007). The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152: 825-831. (Pubitemid 350034974)
48. Jordt SE, Bautista DM, Chuang HH, McKemy DD, Zygmunt PM, Hogestatt ED, et al. (2004). Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427: 260-265. (Pubitemid 38112043)
49. Kagota S, Yamaguchi Y, Nakamura K, Sugiura T, Waku K, Kunitomo M, (2001). 2-Arachidonoylglycerol, a candidate of endothelium-derived hyperpolarizing factor. Eur J Pharmacol 415: 233-238. (Pubitemid 32239469)
50. Kaymakcalan S, Turker RK, (1975). The evidence of the release of prostaglandin-like material from rabbit kidney and guinea-pig lung by (minus)-trans-delta9-tetrahydrocannabinol. J Pharm Pharmacol 27: 564-568.
51. Kenny LC, Baker PN, Kendall DA, Randall MD, Dunn WR, (2002). The role of gap junctions in mediating endothelium-dependent responses to bradykinin in myometrial small arteries isolated from pregnant women. Br J Pharmacol 136: 1085-1088. (Pubitemid 34970058)
52. Kim HJ, Ham SA, Kim MY, Hwang JS, Lee H, Kang ES, et al. (2011). PPARdelta coordinates angiotensin II-induced senescence in vascular smooth muscle cells through PTEN-mediated inhibition of superoxide generation. J Biol Chem 286: 44585-44593.
53. Koura Y, Ichihara A, Tada Y, Kaneshiro Y, Okada H, Temm CJ, et al. (2004). Anandamide decreases glomerular filtration rate through predominant vasodilation of efferent arterioles in rat kidneys. J Am Soc Nephrol 15: 1488-1494. (Pubitemid 38679673)
54. Kozlowska H, Baranowska M, Schlicker E, Kozlowski M, Laudanski J, Malinowska B, (2007). Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery. J Hypertens 25: 2240-2248. (Pubitemid 47537917)
55. Kozlowska H, Baranowska M, Schlicker E, Kozowski M, Laudañski J, Malinowska B, (2008). Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. Br J Pharmacol 155: 1034-1042.
56. Lauckner JE, Jensen JB, Chen H-Y, Lu H-C, Hille B, Mackie K, (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105: 2699-2704. (Pubitemid 351520576)
57. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, et al. (2000). Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 101: 1311-1318. (Pubitemid 30158620)
58. Lawrence DK, Gill EW, (1975). The effects of delta1-tetrahydrocannabinol and other cannabinoids on spin-labeled liposomes and their relationship to mechanisms of general anesthesia. Mol Pharmacol 11: 595-602.
59. Li M, Tanaka Y, Alioua A, Wu Y, Lu R, Kundu P, et al. (2010). Thromboxane A2 receptor and MaxiK-channel intimate interaction supports channel trans-inhibition independent of G-protein activation. Proc Natl Acad Sci USA 107: 19096-19101.
60. Liu CQ, Leung FP, Wong SL, Wong WT, Lau CW, Lu L, et al. (2009). Thromboxane prostanoid receptor activation impairs endothelial nitric oxide-dependent vasorelaxations: the role of Rho kinase. Biochem Pharmacol 78: 374-381.
61. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A, et al. (2000). Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346 (Pt 3): 835-840. (Pubitemid 30171048)
62. Lobato NS, Filgueira FP, Prakash R, Giachini FR, Ergul A, Carvalho MH, et al. (2013). Reduced endothelium-dependent relaxation to anandamide in mesenteric arteries from young obese Zucker rats. PLoS One 8: e63449.
63. McCollum L, Howlett AC, Mukhopadhyay S, (2007). Anandamide-mediated CB1/CB2 cannabinoid receptor-independent nitric oxide production in rabbit aortic endothelial cells. J Pharmacol Exp Ther 321: 930-937. (Pubitemid 46762688)
64. McCulloch AI, Randall MD, (1998). Sex differences in the relative contributions of nitric oxide and EDHF to agonist-stimulated endothelium-dependent relaxations in the rat isolated mesenteric arterial bed. Br J Pharmacol 123: 1700-1706. (Pubitemid 28182054)
65. McNaughton E, Ho WS, (2013). Investigating the role of the putative cannabinoid receptor GPR55 in vascular control in mice. Proceedings of the BPS 6th European Workshop on Cannabinoid Research 2013.
66. McNeish AJ, Jimenez-Altayo F, Cottrell GS, Garland CJ, (2012). Statins and selective inhibition of Rho kinase protect small conductance calcium-activated potassium channel function (K(Ca)2.3) in cerebral arteries. PLoS One 7: e46735.
67. Mair KM, Robinson E, Kane KA, Pyne S, Brett RR, Pyne NJ, et al. (2010). Interaction between anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery. Br J Pharmacol 161: 176-192.
68. Malinowska B, Baranowska-Kuczko M, Schlicker E, (2012). Triphasic blood pressure responses to cannabinoids: do we understand the mechanism? Br J Pharmacol 165: 2073-2088.
69. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J, (1999). PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19: 546-551. (Pubitemid 29135154)
70. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI, (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
71. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
72. Mestre L, Docagne F, Correa F, Loria F, Hernangomez M, Borrell J, et al. (2009). A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol Cell Neurosci 40: 258-266.
73. Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, et al. (2006). N-arachidonoyl l-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci USA 103: 2428-2433. (Pubitemid 43271686)
74. Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K, et al. (2005). Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke 36: 1077-1082.
75. Mo FM, Offertáler L, Kunos G, (2004). Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur J Pharmacol 489: 21-27. (Pubitemid 38520067)
76. 1 receptors. Br J Pharmacol 149: 898-908. (Pubitemid 44851714)
77. Movahed P, Evilevitch V, Andersson TLG, Jönsson BAG, Wollmer P, Zygmunt PM, et al. (2005). Vascular effects of anandamide and N-acylvanillylamines in the human forearm and skin microcirculation. Br J Pharmacol 146: 171-179. (Pubitemid 43079956)
78. Mukhopadhyay S, Chapnick BM, Howlett AC, (2002). Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol Heart Circ Physiol 282: H2046-H2054. (Pubitemid 34663012)
79. Munro S, Thomas KL, Abu-Shaar M, (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65. (Pubitemid 23305569)
80. O'Sullivan S, David AK, Michael DR, (2004a). Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. Br J Pharmacol 142: 435-442. (Pubitemid 38869856)
81. O'Sullivan SE, (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152: 576-582. (Pubitemid 350034977)
82. O'Sullivan SE, Kendall DA, Randall MD, (2004b). Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br J Pharmacol 141: 803-812. (Pubitemid 38446181)
83. O'Sullivan SE, Kendall DA, Randall MD, (2005a). The effects of Delta9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. Br J Pharmacol 145: 514-526. (Pubitemid 40966281)
84. O'Sullivan SE, Kendall DA, Randall MD, (2005b). Vascular effects of [delta]9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. Eur J Pharmacol 507: 211-221. (Pubitemid 40126857)
85. O'Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, Randall MD, (2005c). Novel time-dependent vascular actions of [Delta]9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun 337: 824-831. (Pubitemid 41446988)
86. -9tetrahydrocannabinol. J Pharmacol Exp Ther 317: 428-438.
87. O'Sullivan SE, Randall MD, Gardiner SM, (2007). The in vitro and in vivo cardiovascular effects of Delta9-tetrahydrocannabinol in rats made hypertensive by chronic inhibition of nitric-oxide synthase. J Pharmacol Exp Ther 321: 663-672. (Pubitemid 46624493)
88. O'Sullivan SE, Kendall DA, Randall MD, (2009a). Time-dependent vascular effects of endocannabinoids mediated by peroxisome proliferator-activated receptor gamma (PPARgamma). PPAR Res 2009: 425289.
89. O'Sullivan SE, Sun Y, Bennett AJ, Randall MD, Kendall DA, (2009b). Time-dependent vascular actions of cannabidiol in the rat aorta. Eur J Pharmacol 612: 61-68.
90. Offertaler L, Mo F-M, Bátkai S, Liu J, Begg M, Razdan RK, et al. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63: 699-705. (Pubitemid 36297343)
91. Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, et al. (2006). Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3: 167-175.
92. Parmar N, Ho WS, (2010). N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels. Br J Pharmacol 160: 594-603. doi: 10.1111/j.1476-5381.2009. 00622.x. Epub 2010 Feb 5.
93. Peroni RN, Orliac ML, Becu-Villalobos D, Huidobro-Toro JP, Adler-Graschinsky E, Celuch SM, (2004). Sex-linked differences in the vasorelaxant effects of anandamide in vascular mesenteric beds: role of oestrogens. Eur J Pharmacol 493: 151-160. (Pubitemid 38746944)
94. Plane F, Holland M, Waldron GJ, Garland CJ, Boyle JP, (1997). Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. Br J Pharmacol 121: 1509-1511. (Pubitemid 27343375)
95. Poblete IM, Orliac ML, Briones R, Adler-Graschinsky E, Huidobro-Toro JP, (2005). Anandamide elicits an acute release of nitric oxide through endothelial TRPV1 receptor activation in the rat arterial mesenteric bed. J Physiol 568: 539-551. (Pubitemid 41555456)
96. Pratt PF, Hillard CJ, Edgemond WS, Campbell WB, (1998). N-arachidonoylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol Heart Circ Physiol 274: H375-H381.
97. Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM, (2008). TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28: 6231-6238.
98. Rademacher DJ, Patel S, Ho WS, Savoie AM, Rusch NJ, Gauthier KM, et al. (2005). U-46619 but not serotonin increases endocannabinoid content in middle cerebral artery: evidence for functional relevance. Am J Physiol Heart Circ Physiol 288: H2694-H2701. (Pubitemid 40720647)
99. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman JW, et al. (2007). CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 293: H2210-H2218. (Pubitemid 47605864)
100. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Huffman J, Mackie K, et al. (2008a). CB2 receptor agonists attenuate TNF-{alpha} induced human vascular smooth muscle cell proliferation and migration. FASEB J 22 (1-Meeting Abstracts): 912.39.
101. Rajesh M, Mukhopadhyay P, Hasko G, Huffman JW, Mackie K, Pacher P, (2008b). CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol 153: 347-357.
102. Ramirez SH, Hasko J, Skuba A, Fan S, Dykstra H, McCormick R, et al. (2012). Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J Neurosci 32: 4004-4016.
103. Resstel LB, Tavares RF, Lisboa SF, Joca SR, Correa FM, Guimaraes FS, (2009). 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156: 181-188.
104. Romano MR, Lograno MD, (2006). Cannabinoid agonists induce relaxation in the bovine ophthalmic artery: evidences for CB1 receptors, nitric oxide and potassium channels. Br J Pharmacol 147: 917-925.
105. Romano MR, Lograno MD, (2012). Involvement of the peroxisome proliferator-activated receptor (PPAR) alpha in vascular response of endocannabinoids in the bovine ophthalmic artery. Eur J Pharmacol 683: 197-203.
106. Russo EB, Burnett A, Hall B, Parker KK, (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 1037-1043. (Pubitemid 41570039)
107. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101. (Pubitemid 350166046)
108. Schley M, Ständer S, Kerner J, Vajkoczy P, Schüpfer G, Dusch M, et al. (2009). Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res Bull 79: 333-337.
109. Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, et al. (2012). AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. Neuropharmacology 63: 905-915.
110. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. (1998). Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393: 790-793. (Pubitemid 28299490)
111. Stanke-Labesque F, Mallaret M, Lefebvre B, Hardy G, Caron F, Bessard G, (2004). 2-Arachidonoyl glycerol induces contraction of isolated rat aorta: role of cyclooxygenase-derived products. Cardiovasc Res 63: 155-160. (Pubitemid 38759820)
112. Stanley C, O'Sullivan S, (2011). Characterisation of cannabidiol-induced vasorelaxation in human mesenteric arteries. Proceedings of the BPS Winter Meeting 2011 098P.
113. Stanley C, O'Sullivan S, (2012). The vasorelaxant effects of anandamide in the human mesenteric artery. Proceedings of the BPS Winter Meeting 2012 175P.
114. Stanley CP, O'Sullivan SE, (2014). Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries. Pharmacol Res. pii: S1043-6618(14)00014-0. doi: 10.1016/j.phrs.2014.02.001.
115. Stanley C, Manning G, O'Sullivan S, (2011). Characterisation of 2-arachidonoylglycerol-induced vasorelaxation in human mesenteric arteries P163.
116. Stefano GB, Bilfinger TV, Rialas CM, Deutsch DG, (2000). 2-arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. Pharmacol Res 42: 317-322.
117. Su JY, Vo AC, (2007). 2-Arachidonyl glyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling. Eur J Pharmacol 559: 189-195. (Pubitemid 46295410)
118. Sudhahar V, Shaw S, Imig JD, (2009). Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries. Eur J Pharmacol 607: 143-150.
119. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. (1995). 2-Arachidonoylgylcerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89-97.
120. Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K, (1998). Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun 243: 838-843. (Pubitemid 28414169)
121. Suleimani YM, Hiley CR, (2013). Mechanisms of vasorelaxation induced by oleoylethanolamide in the rat small mesenteric artery. Eur J Pharmacol 702: 1-11.
122. Szekeres M, Nadasy GL, Turu G, Soltesz-Katona E, Toth ZE, Balla A, et al. (2012). Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors. J Biol Chem 287: 31540-31550.
123. Villalon CM, Centurion D, (2007). Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol 376: 45-63.
124. Wagner JA, Varga K, Jarai Z, Kunos G, (1999). Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33 (1 Pt 2): 429-434. (Pubitemid 29065697)
125. Wahn H, Wolf J, Kram F, Frantz S, Wagner JA, (2005). The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. Am J Physiol Heart Circ Physiol 289: H2491-H2496. (Pubitemid 41698562)
126. Waldeck-Weiermair M, Zoratti C, Osibow K, Balenga N, Goessnitzer E, Waldhoer M, et al. (2008). Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci 121: 1704-1717. (Pubitemid 351911827)
127. Wang Y, Wang J, Wang C, Liu J, Shi L, Xu M, et al. (2008). Functional expression of transient receptor potential vanilloid-related channels in chronically hypoxic human pulmonary arterial smooth muscle cells. J Membrane Biol 223: 151-159.
128. Watts SW, Davis RP, (2011). 5-Hydroxtryptamine receptors in systemic hypertension: an arterial focus. Cardiovasc Ther 29: 54-67.
129. Wheal AJ, Randall MD, (2009). Effects of hypertension on vasorelaxation to endocannabinoids in vitro. Eur J Pharmacol 603: 79-85.
130. Wheal AJ, Bennett T, Randall MD, Gardiner SM, (2007). Effects of chronic nitric oxide synthase inhibition on the cardiovascular responses to cannabinoids in vivo and in vitro. Br J Pharmacol 150: 662-671. (Pubitemid 46355560)
131. Wheal AJ, Alexander SP, Randall MD, (2010). Vasorelaxation to N-oleoylethanolamine in rat isolated arteries: mechanisms of action and modulation via cyclooxygenase activity. Br J Pharmacol 160: 701-711.
132. White R, Hiley CR, (1998). The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery. Br J OF Pharmacol 125: 533-541. (Pubitemid 28451492)
133. White R, Ho WS, Bottrill FE, Ford WR, Hiley CR, (2001). Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br J Pharmacol 134: 921-929. (Pubitemid 33016165)
134. Yang D, Feletou M, Boulanger CM, Wu HF, Levens N, Zhang JN, et al. (2002). Oxygen-derived free radicals mediate endothelium-dependent contractions to acetylcholine in aortas from spontaneously hypertensive rats. Br J Pharmacol 136: 104-110. (Pubitemid 34499322)
135. Zador F, Otvos F, Benyhe S, Zimmer A, Paldy E, (2012). Inhibition of forebrain mu-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves mu-opioid receptors. Neurochem Int 61: 378-388.
136. Zavitsanou K, Wang H, Dalton VS, Nguyen V, (2010). Cannabinoid administration increases 5HT1A receptor binding and mRNA expression in the hippocampus of adult but not adolescent rats. Neuroscience 169: 315-324.
137. Zhang X, Maor Y, Wang JF, Kunos G, Groopman JE, (2010). Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol 160: 1583-1594.
138. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, et al. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452-457. (Pubitemid 29361798)
139. Zygmunt PM, Andersson DA, Hogestatt ED, (2002). Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 22: 4720-4727. (Pubitemid 37465687)